Dosimetric analysis and toxicity comparison of Bone Marrow sparing IMRT vs Four field Conformal technique with concurrent Chemotherapy for the treatment of Cervical Carcinoma -A Randomized Prospective Single Institutional Study

GHRITASHEE BORA0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Histologically proven cervical cancer patients.
•2.Stage II A to IV A
•3.Age 18 â?? 65 years
•4.Karnoffskyâ??s Performance Scale(KPS) score >70.
•5.Patients with adequate Bone Marrow ,renal and hepatic function(to be obtained <14 days prior to registration).
•Haemoglobin >10 gm/dl.
•WBC >4000/mmÂ³
•ANC >1500cells/mmÂ³
•Platelets >100,000cells/mmÂ³
•Creatinine Clearance >50 ml/min
•6.Prior to registration CT/MRI of abdomen and pelvis must be performed.
•7.Chest X ray should be performed prior to treatment.
•8.Patient must sign a study-specific informed consent.

•1.Distant metastasis discovered by clinical or imaging examination.
•2.Bladder control problems that make the patient unable to comply with Bladder filling protocols.
•3.Prior Radiation Therapy to the pelvis that would result in overlap of radiation therapy fields.
•4.Patients with serious active co-morbidities defined as-
•Unstable Angina and/or Congestive heart failure requiring hospitalisation within last 6 months.
•Trans mural myocardial infarction within last 6 months.
•Exacerbation of COPD/ other respiratory illness requiring hospitalisation at the time of registration.
•Hepatic insufficiency resulting in clinical jaundice.
•AIDS based upon current CDC definition.
•5.Cervical cancer patients with prior treatment with Platinum based Chemotherapy.

发起方

GHRITASHEE BORA